Juva Life Q2 Revenue Grows 144%, What About Net Loss?
Juva Life Q2 Revenue Grows 144%, What About Net Loss?
Juva Life Inc. (OTCQB:JUVAF) (CSE:JUVA) (FRANKFURT:4VV) Q2 2022 revenue was $1.8 million, a 144% increase over the same period in the previous year.
JUVA Life Inc.(场外交易：JUVAF)(CSE：JUVA)(法兰克福：4VV)2022年第二季度收入曾经是180万美元, a 增长144%比上一年同期有所增加。
Q2 2022 Highlights
2022年第二季度亮点
-
Net loss decreased from $2.8 million in Q2 2021 to $1.9 million in Q2 2022, pointing to a positive trend in cost-reduction and healthy growth.
-
The company completed an $11.8 million financing in Q2 that allowed for the purchase of its Stockton facility.
-
Operationally, in the second quarter of 2022, Juva continued its preclinical research program on novel compound Juva-041. The compound, which has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, is currently being scaled up to support pre-clinical and non-clinical pharma development studies.
-
Beyond its clinical research programs, Juva also relaunched its WIRB-approved JuLi Registry study with the goal of cultivating one of the largest data sets on the medicinal applications of cannabis use to exist to date.
-
Through its cannabis operations, the company completed multiple milestones including the launch of in-house brands `Secret Sauce" and "Flos." It also received local provisional licensing of its cannabis retail storefront location in Redwood City.
-
NET损失从2021年第二季度的280万美元下降到190万美元2022年第二季度，显示出降低成本和健康增长的积极趋势。
-
该公司完成了一项$11.8 百万融资在第二季度，这允许购买其斯托克顿工厂。
-
在操作上，2022年第二季度，Juva继续其关于新型化合物Juva-041的临床前研究计划。这种化合物在炎症的表型分析中表现出了强大的抗炎特性，目前正在扩大规模，以支持临床前和非临床药物开发研究。
-
除了其临床研究计划，Juva还重新启动了其WIRB批准的JULI注册研究其目标是培育迄今为止最大的大麻使用医用数据集之一。
-
通过大麻业务，该公司完成了多个里程碑，包括推出自有品牌秘制酱料“和”鲜花.“它还收到了当地的临时发牌其位于红杉城的大麻零售店店面。
"I could not be more excited by the momentum Juva is experiencing in both its cannabis operations and clinical research," stated Doug Chloupek, CEO and founder of Juva. "While many of our industry peers in California are struggling to expand their businesses, or even survive, Juva is experiencing quarter-over-quarter growth in revenue, while we continue to cut costs and increase margins. As we continue the permitting of our upcoming Redwood City retail location, we will further optimize our Stockton facility, where we continue to increase yield with minimal additional costs. On the pharmaceutical research side, we continue to move at an unprecedented pace in proving the therapeutic potential of our novel compound, Juva-041. All said, I believe we are heading in a positive direction as an organization and I look forward to updating the market during our webinar next week!"
他说：“我对Juva在大麻手术和临床研究方面所经历的势头感到非常兴奋。”道格·克洛佩克，Juva的首席执行官兼创始人。当我们在加州的许多行业同行都在努力扩大业务，甚至生存时，Juva的收入却在按季度增长，而我们则在继续削减成本和提高利润率。随着我们继续批准即将到来的红木城零售点，我们将进一步优化我们的斯托克顿工厂，在那里我们将以最低的额外成本继续提高产量。在药物研究方面，我们继续以前所未有的速度证明我们的新型化合物Juva-041的治疗潜力。所有人都说，我相信我们作为一个组织正在朝着积极的方向前进，我期待着在下周的网络研讨会上更新市场！
Price Action
价格行动
Juva Life shares were trading 3.35% higher at $0.1387 per share at the time of writing Wednesday morning.
截至周三上午撰写本文时，日联人寿股价上涨3.35%，至每股0.1387美元。
Photo by Thiago Patriota on Unsplash
Thiago Patriota在Unspash上的照片
Related News
相关新闻
Juva Life Q1 2022 Revenue Grows 97% YoY
JUVA Life 2022年第一季度收入同比增长97%
Is Market Pressure Hindering Cannabis Real Estate Investment? Ask Rob Sechrist At The Cannabis Capital Conference In September
市场压力是否阻碍了大麻房地产投资？问问9月大麻首都会议上的Rob Sechrist
3 Financial Players To Watch In Cannabis: Alternative Funding Options For A Burgeoning Industry
大麻行业值得关注的3个金融参与者：新兴行业的替代融资选择
译文内容由第三方软件翻译。